Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XUNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.3 (Omicron)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.3.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.1.16.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.372NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FQ.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JB.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.17NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FL.3.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FZ.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
DV.7.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FL.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FL.30.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.5.68NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CD.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.122.3 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
C.8NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.425NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.144NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.288NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.249NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.378NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.97NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.9NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.439NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.408NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.256NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.47NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.38NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.251NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
A.2.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.256NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.26NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.77NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.34NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.248NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.32NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.128NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.36.33NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.405NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.296NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.412NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AC.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
C.27NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.421NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.364NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.82NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.61NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
Q.7 (Alpha)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.460NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used